Updates on immunotherapy for colorectal cancer

Aparna Kalyan*, Sheetal Kircher, Hiral Shah, Mary Mulcahy, Al Benson

*Corresponding author for this work

Research output: Contribution to journalReview article

41 Scopus citations

Abstract

Despite significant advances in standard of care therapies, the 5-year survival rate for metastatic colorectal cancer (CRC) remains around 12%. Immunotherapy has not provided the stellar advances in colorectal cancer that has been seen in other malignancies. Immunotherapy appears to play a pivotal role in microsatellite unstable CRC tumors where the response rates are profound. These results have led to FDA approval of pembrolizumab for MSI-H CRC tumors. Additional research into several new immune agents including IDO inhibitors, vaccine therapy and combinatorial agents are being evaluated for CRC. This review will provide an overview of the approaches currently being investigated.

Original languageEnglish (US)
Pages (from-to)160-169
Number of pages10
JournalJournal of Gastrointestinal Oncology
Volume9
Issue number1
DOIs
StatePublished - Feb 1 2018

    Fingerprint

Keywords

  • Colorectal cancer (CRC)
  • Immunotherapy
  • Microsatellite instability (MSI)
  • Vaccine therapy

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this